Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Blueprint Medicines Corporation (BPMC : NSDQ)

• Company Description    Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases. Number of Employees: 649

• Price / Volume Information    Yesterday's Closing Price: $128.11 Daily Weekly Monthly 20 Day Moving Average: 6,957,207 shares Shares Outstanding: 64.58 (millions) Market Capitalization: $8,273.62 (millions) Beta: 0.84 52 Week High: $128.45 52 Week Low: $73.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.40% 21.05% 12 Week 56.84% 28.92% Year To Date 46.88% 39.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 45 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-374-7580 fax: - ir@blueprintmedicines.com http://www.blueprintmedicines.com

• General Corporate Information    Officers Kathryn Haviland - President; Chief Executive Officer and Director Jeffrey W. Albers - Chairman of the Board of Directors Michael Landsittel - Chief Financial Officer Ariel Hurley - Senior Vice President Daniella Beckman - Director Peer Information Blueprint Medicines Corporation (CORR.) Blueprint Medicines Corporation (RSPI) Blueprint Medicines Corporation (CGXP) Blueprint Medicines Corporation (BGEN) Blueprint Medicines Corporation (GTBP) Blueprint Medicines Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09627Y109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 64.58 Most Recent Split Date: (:1) Beta: 0.84 Market Capitalization: $8,273.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 24.18 Price/Cash Flow: - Price / Sales: 14.72 EPS Growth vs. Year Ago Period: 43.94% vs. Previous Quarter: 6.33% Sales Growth vs. Year Ago Period: 55.45% vs. Previous Quarter: 2.08% ROE 03/31/25 - -64.60 12/31/24 - -77.49 09/30/24 - -112.30 ROA 03/31/25 - -17.22 12/31/24 - -20.84 09/30/24 - -26.87 Current Ratio 03/31/25 - 2.80 12/31/24 - 2.85 09/30/24 - 3.32 Quick Ratio 03/31/25 - 2.75 12/31/24 - 2.80 09/30/24 - 3.27 Operating Margin 03/31/25 - -36.61 12/31/24 - -47.31 09/30/24 - -69.45 Net Margin 03/31/25 - -27.70 12/31/24 - -13.19 09/30/24 - -29.48 Pre-Tax Margin 03/31/25 - -27.38 12/31/24 - -12.94 09/30/24 - -29.33 Book Value 03/31/25 - 5.30 12/31/24 - 4.70 09/30/24 - 4.93 Inventory Turnover 03/31/25 - 1.47 12/31/24 - 1.12 09/30/24 - 0.65 Debt-to-Equity 03/31/25 - 1.01 12/31/24 - 1.15 09/30/24 - 1.09 Debt-to-Capital 03/31/25 - 50.13 12/31/24 - 53.46 09/30/24 - 52.17

Powered by Zacks Investment Research ©